Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.
Nisha R AcharyaSivakumar R RathinamRadhika ThundikandyAnuradha KanakathS Bala MuruganR VedhanayakiJohn A GonzalesLyndell L LimEric B SuhlerHassan A Al-DhibiThuy DoanLourdes Arellanes-GarciaAlison CoyneTravis C PorcoJessica G Shanthanull nullPublished in: American journal of ophthalmology (2024)
MTX and MMF have comparable outcomes as corticosteroid-sparing immunosuppressive therapies for VKH. Visual acuity improvement was greater in acute vs chronic VKH. NOTE: Publication of this article is sponsored by the American Ophthalmological Society TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00182929.